0000899243-21-000412.txt : 20210105
0000899243-21-000412.hdr.sgml : 20210105
20210105170903
ACCESSION NUMBER: 0000899243-21-000412
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210101
FILED AS OF DATE: 20210105
DATE AS OF CHANGE: 20210105
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bailey John E. (Jack) Jr.
CENTRAL INDEX KEY: 0001806147
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38096
FILM NUMBER: 21506922
MAIL ADDRESS:
STREET 1: C/O G1 THERAPEUTICS, INC.
STREET 2: 700 PARK OFFICES DRIVE, SUITE 200
CITY: RESEARCH TRIANGLE PARK
STATE: NC
ZIP: 27709
FORMER NAME:
FORMER CONFORMED NAME: Bailey John F. (Jack) Jr.
DATE OF NAME CHANGE: 20200310
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: G1 Therapeutics, Inc.
CENTRAL INDEX KEY: 0001560241
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 263648180
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 700 PARK OFFICES DRIVE
STREET 2: SUITE 200
CITY: RESEARCH TRIANGLE PARK
STATE: NC
ZIP: 27709
BUSINESS PHONE: 919-213-9835
MAIL ADDRESS:
STREET 1: 700 PARK OFFICES DRIVE
STREET 2: SUITE 200
CITY: RESEARCH TRIANGLE PARK
STATE: NC
ZIP: 27709
FORMER COMPANY:
FORMER CONFORMED NAME: G-Zero Therapeutics, Inc.
DATE OF NAME CHANGE: 20121012
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-01-01
0
0001560241
G1 Therapeutics, Inc.
GTHX
0001806147
Bailey John E. (Jack) Jr.
C/O G1 THERAPEUTICS
700 PARK OFFICES DR, SUITE 200
RESEARCH TRIANGLE PARK
NC
27709
1
1
0
0
President and CEO
Common Stock
2021-01-01
4
A
0
213333
0.00
A
221333
D
Stock Options (Right to Buy)
17.99
2021-01-01
4
A
0
320000
0.00
A
2031-01-01
Common Stock
320000
320000
D
Represents a restricted stock unit ("RSU") award that vests one-third (1/3rd) on each of the first, second and third anniversaries of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.
Each RSU represents a contingent right to receive one share of Issuer common stock.
Represents 8,000 shares of common stock and 213,333 restricted stock units.
The shares underlying this option vest as to 34% of the shares on January 1, 2022, with the remainder vesting in eight equal quarterly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
/s/ James Stillman Hanson, attorney-in-fact
2021-01-05